Survival Outcomes by Frailty and Comorbidities in Veterans Treated With Abiraterone and Enzalutamide for Metastatic Castration‐Resistant Prostate Cancer
Meghana Yellanki,
Jennifer La,
Danne C. Elbers,
Nhan V. Do,
Channing J. Paller,
Nathanael R. Fillmore,
Martin W. Schoen Prostate
· Wiley
· 2026-11-14
· DOI: 10.1002/pros.70247
The publisher did not provide an abstract — full text is available via the link below.
Meghana Yellanki, Jennifer La, Danne C. Elbers, Nhan V. Do, Channing J. Paller, Nathanael R. Fillmore et al. Survival Outcomes by Frailty and Comorbidities in Veterans Treated With Abiraterone and Enzalutamide for Metastatic Castration‐Resistant Prostate Cancer. // Prostate. – 2026. – DOI: 10.1002/pros.70247. – URL: https://onlinelibrary.wiley.com/doi/10.1002/pros.70247?af=R
Meghana Yellanki, Jennifer La, Danne C. Elbers, Nhan V. Do, Channing J. Paller, Nathanael R. Fillmore, & Martin W. Schoen (2026). Survival Outcomes by Frailty and Comorbidities in Veterans Treated With Abiraterone and Enzalutamide for Metastatic Castration‐Resistant Prostate Cancer. Prostate. https://doi.org/10.1002/pros.70247
Meghana Yellanki, et al. “Survival Outcomes by Frailty and Comorbidities in Veterans Treated With Abiraterone and Enzalutamide for Metastatic Castration‐Resistant Prostate Cancer.” Prostate, 2026. doi:10.1002/pros.70247.
@article{Yellanki2026,
title = {Survival Outcomes by Frailty and Comorbidities in Veterans Treated With Abiraterone and Enzalutamide for Metastatic Castration‐Resistant Prostate Cancer},
author = {Yellanki, Meghana and La, Jennifer and Elbers, Danne C. and Do, Nhan V. and Paller, Channing J. and Fillmore, Nathanael R. and Schoen, Martin W.},
journal = {Prostate},
year = {2026},
doi = {10.1002/pros.70247},
url = {https://onlinelibrary.wiley.com/doi/10.1002/pros.70247?af=R}
}
Objective To assess prostate‐specific antigen (PSA) testing according to income, age, and region of residence in Sweden. Patients and Methods We conducted a nationwide, population‐based open cohort study of men aged 40–90 years in...